


## PHARMACEUTICAL 2022

## Prelude Therapeutics Inc Rank 230 of 475





## PHARMACEUTICAL 2022

## Prelude Therapeutics Inc Rank 230 of 475

The relative strengths and weaknesses of Prelude Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Prelude Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 199% points. The greatest weakness of Prelude Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 99% points.

The company's Economic Capital Ratio, given in the ranking table, is -87%, being 190% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	295,115
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,201
Liabilities, Non-Current	0
Other Assets	6,054
Other Compr. Net Income	-711
Other Expenses	0
Other Liabilities	0
Other Net Income	2,041
Property and Equipment	3,929
Research and Development	86,778
Revenues	0
Selling, General and Administrative Expense	26,957

Output Variable	Value in 1000 USD
Assets	305,098
Liabilities	19,201
Expenses	113,735
Stockholders Equity	285,897
Net Income	-111,694
Comprehensive Net Income	-112,050
Economic Capital Ratio	-87%